middle.news
Dimerix’s DMX-200 Trial Clears Sixth Safety Review, Advancing Hope for FSGS Patients
1:56am on Monday 2nd of June, 2025 AEST
•
Biotechnology
Read Story
Dimerix’s DMX-200 Trial Clears Sixth Safety Review, Advancing Hope for FSGS Patients
1:56am on Monday 2nd of June, 2025 AEST
Key Points
Sixth Independent Data Monitoring Committee (IDMC) review completed successfully
No safety concerns identified; trial continues unchanged
DMX-200 shows strong emerging safety profile in FSGS patients
Next IDMC review scheduled for Q4 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE